2017

Ultragenyx to acquire Dimension Therapeutics

Wednesday, October 4, 2017

Ultragenyx Pharmaceutical, a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Dimension Therapeutics have entered into a definitive merger agreement under which Ultragenyx will acquire all of the outstanding shares of common stock of Dimension for $6.00 per share, or approximately $151 million in cash, based on currently outstanding shares. The transaction is structured as a tender offer and will be funded through Ultragenyx’s existing cash resources.

[Read More]

Mitochon Pharmaceuticals to support mitochondrial research in Parkinson’s

Wednesday, October 4, 2017

Mitochon Pharmaceuticals announced that it was awarded a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to help develop its mitochondrial targeted compounds for treating Parkinson’s disease. The funding will go to pivotal animal studies to assess the benefits of Mitochon’s compounds in ameliorating the deficits associated with dopaminergic neuron loss, the hallmark of Parkinson’s disease. If successful, Mitochon’s compounds, MP101 ad MP201 could be in patients as early as 2019.

[Read More]

PatientKeeper launches PatientKeeper Charge-Note Reconciliation

Wednesday, October 4, 2017

PatientKeeper, a provider of healthcare applications for physicians, announced PatientKeeper Charge-Note Reconciliation, an automated tool that helps healthcare providers ensure that all reimbursable physician services are charged and that all charges are documented. Benefits to provider organizations include increased revenue from avoiding missed charges, streamlined administrative processes for billers and coders, and a mechanism to identify potentially missing documentation that could put an organization at risk during a RAC audit.

[Read More]

Certara launches Phoenix PK/PD modeling and simulation software Version 8.0

Tuesday, October 3, 2017

Certara, a global provider of model-informed drug development and regulatory science, announced the launch of Phoenix 8.0. Phoenix is the most advanced, intuitive, and widely-used software for pharmacokinetic (PK), pharmacodynamic (PD) and toxicokinetic (TK) modeling and simulation. Included in this Phoenix rollout are Phoenix WinNonlin 8.0, Phoenix NLME 8.0, Phoenix Validation Suite 8.0 and Phoenix in vitro-in vivo correlation (IVIVC) Toolkit 8.0.

[Read More]